[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day]. 1986

J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
January 1987, Bulletin du cancer,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
July 1989, European journal of cancer & clinical oncology,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
October 1985, Tumori,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
June 1998, Annals of oncology : official journal of the European Society for Medical Oncology,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
September 1981, The New England journal of medicine,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
October 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
October 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
June 1980, Biochemical Society transactions,
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
December 1985, Wiener medizinische Wochenschrift (1946),
J Bonneterre, and H Coppens, and L Mauriac, and J Rouesse, and P Fargeot, and R Metz, and J P Armand, and A Mathieu, and M Tubiana, and P Cappelaere
February 1981, The Australian and New Zealand journal of surgery,
Copied contents to your clipboard!